GBP110.40
0.11% today
London, Jan 22, 05:44 pm CET
ISIN
GB0009895292
Symbol
AZN
Sector
Industry

AstraZeneca Stock price

GBP110.40
+6.18 5.93% 1M
-11.45 9.40% 6M
+5.72 5.46% YTD
+6.77 6.54% 1Y
+32.53 41.78% 3Y
+42.18 61.83% 5Y
+76.64 227.05% 10Y
London, Closing price Wed, Jan 22 2025
-0.12 0.11%
ISIN
GB0009895292
Symbol
AZN
Sector
Industry

Key metrics

Market capitalization GBP171.37b
Enterprise Value GBP191.29b
P/E (TTM) P/E ratio 33.46
EV/FCF (TTM) EV/FCF 24.42
EV/Sales (TTM) EV/Sales 4.74
P/S ratio (TTM) P/S ratio 4.24
P/B ratio (TTM) P/B ratio 5.64
Dividend yield 2.06%
Last dividend (FY23) GBP2.28
Revenue growth (TTM) Revenue growth 10.00%
Revenue (TTM) Revenue GBP40.38b
EBIT (operating result TTM) EBIT GBP7.99b
Free Cash Flow (TTM) Free Cash Flow GBP7.83b
Cash position GBP3.68b
EPS (TTM) EPS GBP3.30
P/E forward 25.12
P/S forward 3.92
EV/Sales forward 4.38
Show more

Create a Free Account to create an AstraZeneca alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

AstraZeneca Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a AstraZeneca forecast:

26x Buy
81%
6x Hold
19%

Analyst Opinions

32 Analysts have issued a AstraZeneca forecast:

Buy
81%
Hold
19%

Financial data from AstraZeneca

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
40,380 40,380
10% 10%
100%
- Direct Costs 10,644 10,644
0% 0%
26%
29,736 29,736
14% 14%
74%
- Selling and Administrative Expenses 8,157 8,157
9% 9%
20%
- Research and Development Expense 9,119 9,119
13% 13%
23%
12,460 12,460
19% 19%
31%
- Depreciation and Amortization 4,471 4,471
1% 1%
11%
EBIT (Operating Income) EBIT 7,989 7,989
34% 34%
20%
Net Profit 5,119 5,119
7% 7%
13%

In millions GBP.

Don't miss a Thing! We will send you all news about AstraZeneca directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AstraZeneca Stock News

Positive
Seeking Alpha
about 2 hours ago
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners.
Neutral
PRNewsWire
about 16 hours ago
NEW YORK , Jan. 21, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period"), of the February 21, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased AstraZenec...
Positive
Seeking Alpha
one day ago
Bloomberg Intelligence analysts identified 50 watchable firms for 2025, focusing on catalysts like new leadership, asset sales, acquisitions, and new products. 14 of 35 dividend-paying companies meet the "safer" criteria with free cash flow yields exceeding dividend yields, inviting closer investor scrutiny. Top ten Bloomberg Dividend Focus stocks for 2025 projected net gains between 11.62% and...
More AstraZeneca News

Company Profile

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Pascal Soriot
Employees 89,900
Founded 1992
Website www.astrazeneca.co.uk

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today